What is HC Wainwright’s Estimate for OmniAb Q2 Earnings?

OmniAb, Inc. (NASDAQ:OABI) – Research analysts at HC Wainwright reduced their Q2 2026 earnings estimates for OmniAb in a report issued on Friday, May 8th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.10) per share for the quarter, down from their previous forecast of ($0.09). The consensus estimate for OmniAb’s current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for OmniAb’s Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.38) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at ($0.09) EPS.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. The company had revenue of $14.43 million during the quarter, compared to analyst estimates of $5.60 million. OmniAb had a negative net margin of 187.59% and a negative return on equity of 20.31%.

Several other analysts also recently weighed in on OABI. Wall Street Zen upgraded OmniAb from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Benchmark reiterated a “buy” rating on shares of OmniAb in a research report on Friday, March 6th. Finally, Weiss Ratings downgraded OmniAb from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, OmniAb has a consensus rating of “Hold” and an average target price of $3.00.

OmniAb Stock Up 0.6%

NASDAQ OABI opened at $1.67 on Tuesday. OmniAb has a 52 week low of $1.22 and a 52 week high of $2.30. The firm has a market capitalization of $241.78 million, a price-to-earnings ratio of -3.63 and a beta of 0.07. The company has a fifty day moving average of $1.63 and a two-hundred day moving average of $1.73.

Institutional Trading of OmniAb

Institutional investors and hedge funds have recently made changes to their positions in the company. Boothbay Fund Management LLC bought a new stake in shares of OmniAb in the fourth quarter valued at about $88,000. The Manufacturers Life Insurance Company boosted its holdings in shares of OmniAb by 20.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock valued at $78,000 after buying an additional 7,624 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in shares of OmniAb by 114.2% in the 3rd quarter. Squarepoint Ops LLC now owns 35,431 shares of the company’s stock valued at $57,000 after buying an additional 18,890 shares in the last quarter. Corient Private Wealth LLC bought a new stake in shares of OmniAb in the 2nd quarter valued at about $53,000. Finally, Cerity Partners LLC raised its stake in shares of OmniAb by 111.5% during the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after acquiring an additional 11,919 shares in the last quarter. 72.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at OmniAb

In related news, CEO Matthew W. Foehr sold 19,244 shares of OmniAb stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $1.49, for a total value of $28,673.56. Following the completion of the sale, the chief executive officer directly owned 4,420,492 shares in the company, valued at $6,586,533.08. The trade was a 0.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 117,703 shares of company stock valued at $193,597 in the last ninety days. Insiders own 9.80% of the company’s stock.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.